How we can help you to present a clear and compelling case for investment.
The share performance of most insurers continues to be disappointing. While this is principally a reflection of economic uncertainty and market volatility, confusing market reporting has also played a part by making it difficult for analysts and investors to judge the company strategy and discern the true value being created within the business. Investors’ underlying concern is that disjointed disclosures may be symptomatic of poor management information and a lack of strategic coherence.
The planned new IFRS insurance standard (IFRS Phase II) will bring welcome standardisation across insurers' market reporting. But it will have important implications for product design, the trajectory of earnings and how your business is judged by analysts and investors.
IFRS 9 for Financial Instruments is coming in 2018, are you prepared for its impact on your business?
Keep up with insurance regulation. Solvency II and IFRS overlap so save money and time by doing things once, and improve your market reporting.